2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
2
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphangioleiomyomatosis
1
Liver Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Chemoprevention
1
Carcinoma, Hepatocellular
1
Interventions
Sirolimus
10
Everolimus
6
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Octreotide
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphangioleiomyomatosis
×
Resveratrol
×
Clear all
NCT03253913
2023-02-01
RESULT
University of Cincinnati
Phase 2
Completed
25 enrolled
11 charts